Nanotechnology has been referred to as potentially being the next technical revolution that could change the modern world. Perhaps the developments seen to date do not yet match this build up, but the combined investment by governments, universities, and industry is significant with global government investment exceeding $9 billion annually and growing. The United States government alone has invested over $27 billion since from 2001 – 2019.2 The global nanotechnology market has been estimated to be between $10 – 50 billion annually depending on definitions and sources.
The development of the Blazar™ Rodent Panel allows biopharma to move away from traditional in vivo antibody production assays when characterizing cell banks of rodent origin used in the production of biologicals.
The standardization of biologics manufacturing processes has given product developers multiple viable options for producing monoclonal antibodies (mAbs), including building an in-house mAb production system or partnering with a contract biologics manufacturer. This article shares a success story for an early-stage technology transfer and the parameters to consider to stay ahead of your competitors.
mRNA has emerged as a promising modality for a wide range of therapeutics and vaccines and could become the break-through technology of this century. This technology will not only revolutionize the field of vaccine development by allowing a rapid response to disease outbreaks, it will also help to address diseases of unmet medical need with gene therapy approaches or cancer treatments. Learn more with our white paper.